Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: Canada’s biomanufacturing capabilities are growing
After returning from CellCAN’s 2022 Strategic Forum in Ottawa, Ontario, where Canada’s cell and gene therapy biomanufacturing community came together to share information and network, it is clear that the country’s biomanufacturing landscape is improving. As I and many others have written since the start of the COVID-19 pandemic, the crisis highlighted significant gaps in […]
Right Turn: Regenerative medicine outside the university classroom
Now is a fantastic time to be an undergraduate student, graduate student or postdoc (sometimes referred to as trainees or highly qualified personnel) interested in regenerative medicine. In addition to the education you receive in the classroom or lab, your university will have department or student-run activities for networking or to help you enhance your […]
Right Turn: Seeking science distractions while on vacation
Hello from Alaska! I’m on vacation this week – hopefully you are as well. After many days at sea and lots of napping, reading, walking, spotting local wildlife, eating, Netflix and Wordle, it’s time for something that feels like work without being work. Since I haven’t shared a good science parody video in a looong […]
Right Turn: Experts weigh in on manufacturing of CGTs at JLABS-CCRM event
If manufacturing is the gatekeeper to success in the cell and gene therapy space, it’s not surprising that the topic regularly comes up when industry leaders come together to discuss the future or to tackle the challenges we face in commercializing cell and gene therapies (CGTs). Such was the case earlier this month at the […]